Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Weekly Radiation Therapy Clear all
Terminated Phase 1 Interventional

Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer

NCT01677845
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 23, 2026, 6:54 AM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

NCT03699033
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
2.5 Gy/fraction, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Stephanie Smiddy
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 23, 2026, 6:54 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

NCT00226746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Paclitaxel and gemcitabine
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 23, 2026, 6:54 AM EDT
Withdrawn Phase 1 Interventional

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

NCT02989870
View directory record Official record
Conditions
HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 23, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Active, not recruiting Not applicable Interventional

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NCT02945631
View directory record Official record
Conditions
Locally Advanced HPV Positive Oropharynx Cancer
Interventions
PTV56, PTV50.4
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Completed No phase listed Observational

Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer

NCT02649569
View directory record Official record
Conditions
Digestive System Carcinoma, Head and Neck Carcinoma, Lung Carcinoma
Interventions
Monitoring Device, Quality-of-Life Assessment
Device · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)

NCT02272270
View directory record Official record
Conditions
Newly Diagnosed High Grade Glioma
Interventions
Minocycline with chemoradiation (temozolomide and radiation therapy)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 23, 2026, 6:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

NCT00226941
View directory record Official record
Conditions
Rectal Cancer, Colo-rectal Cancer
Interventions
Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl)
Drug · Radiation
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 23, 2026, 6:54 AM EDT
Completed No phase listed Observational

Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

NCT05462951
View directory record Official record
Conditions
Uterine Cervix Cancer
Interventions
Standard
Radiation
Lead sponsor
Denise Fabian
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Exercise Therapy in Radiation Therapy

NCT03905356
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Exercise Therapy
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 23, 2026, 6:54 AM EDT
Terminated Phase 3 Interventional

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

NCT01875653
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma
Interventions
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

NCT00601627
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
panitumumab, capecitabine, fluorouracil, gemcitabine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
281
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

NCT00350142
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic Body Radiotherapy, Gemcitabine, 4D pancreatic protocol CT scan, FDG PET scan
Radiation · Drug · Other
Lead sponsor
Albert Koong
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00528866
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, flutamide, LHRH agonist, 3-dimensional conformal radiation therapy, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
69
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Cisplatin + RT for Triple Negative Breast Cancer

NCT01674842
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy, Cisplatin
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 23, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional Results available

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00288054
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
77
States / cities
Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

NCT00225420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00003546
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 23, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

NCT03907488
View directory record Official record
Conditions
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
711
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Recruiting No phase listed Observational

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

NCT00568490
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Lip Cancer, Lip Neoplasms, Head and Neck Cancers
Interventions
Tumor biopsy, Phlebotomy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

NCT02871843
View directory record Official record
Conditions
Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma
Interventions
RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2), TMZ Maintenance
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

NCT01420250
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Drug · Radiation · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
View directory record Official record
Conditions
Glioblastoma, Brain Tumor, GBM
Interventions
Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 23, 2026, 6:54 AM EDT